Skip to content
DataLookout
Menu

NCT07091630

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

StatusRecruiting
PhasePhase 3
Sponsorargenx
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 18 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Study sites: 94 to 95
  2. Minor Trial sites expanded: 89 → 94 locations
  3. Minor Site contacts updated at 1 of 89 sites
  4. Minor Trial sites expanded: 85 → 89 locations
  5. Minor Trial sites expanded: 82 → 85 locations
    • Site details revised at 24 of 85 sites
  6. Minor Study sites: 82 to 85
  7. Notable Eligibility criteria expanded, about 10 words
    • Trial sites expanded: 78 → 82 locations
    • Secondary endpoints: details revised at 11 of 22 entries
  8. Minor Trial sites expanded: 71 → 78 locationsv11
  9. Minor Trial sites expanded: 61 → 71 locationsv10
  10. Minor Trial sites expanded: 56 → 61 locationsv9
  11. Minor Trial sites expanded: 43 → 56 locationsv8
  12. Minor Trial sites expanded: 19 → 43 locationsv7
  13. Minor Study sites: 14 to 19v6
  14. Minor Study sites: 9 to 14v5
  15. Minor Study sites: 2 to 9v4
  16. Minor Study sites: 1 to 2v3
  17. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria expanded, about 26 words
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 2025 to Sep 16, 2025
    v2
  18. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Reduction of ≥1 point compared with baseline in aINCAT score at week 24
Timeframe: Up to 24 weeks

Secondary (22)

Change from baseline in I-RODS centile points score
Change from baseline in MRC-SS at week 24
Change from baseline in grip strength (3-day moving average) in the dominant hand at week 24
Time to reduction of ≥1 point from baseline in aINCAT score
Change from baseline in TUG
Show 17 moreShow less
Time to increase of ≥1 point compared with baseline in aINCAT score up to week 24
Change from baseline in grip strength (3-day moving average) of both hands over time
Change from baseline in grip strength (daily average) for both hands
Change from baseline in MRC-SS over time
Change from baseline in aINCAT score over time
Change from baseline in EQ-5D-5L over time
Change from baseline in RT-FSS over time
Change from baseline in BPI-SF over time
PGI-S values over time
PGI-C values over time
Incidence of ADA against empasiprubart in serum
Incidence of NAb against empasiprubart in serum
Incidence of AEs and SAEs
Percentage change from baseline in free C2 and total C2 over time
Serum concentrations of empasiprubart over time
Reduction of ≥1 point in aINCAT over time
Increase of ≥1 point from baseline in aINCAT over time

Arms and interventions

Part A - EmpasiprubartExperimental

Participants receive empasiprubart during part A

Part A - PlaceboPlacebo comparator

Participants receive placebo during part A

Part B - EmpasiprubartExperimental

Participants receive empasiprubart during part B. Participants from the empasiprubart arm in part A will receive placebo once to maintain the blind of part A.

Biologicals: Empasiprubart IV

Other: Placebo IV

Sites

95 sites in 25 countries

United States 14, China 9, Georgia 8, Italy 8, Brazil 7, Bulgaria 5, France 5, Japan 4, Romania 4, United Kingdom 4, Argentina 3, Colombia 3, Poland 3, Slovakia 3, Austria 2, Greece 2, Israel 2, South Korea 2, Czechia 1, Denmark 1, Estonia 1, Hungary 1, Moldova 1, Netherlands 1, Singapore 1